Spectranetics Receives CE Mark Approval for AngioSculptX

August 10, 2016—The Spectranetics Corporation announced receipt of CE Mark approval for the AngioSculptX drug-coated percutaneous transluminal coronary angioplasty scoring balloon catheter. The device is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis. 

Prof. Bruno Scheller, MD, of Saarlandes University Clinic in Homburg, Germany, commented in the company’s announcement, “AngioSculptX represents a unique coronary scoring technology that incorporates a drug coating. Given its clinical results, it is a significant advancement in therapy options for patients.”

Spectranetics noted that as part of the original acquisition of AngioScore, Inc. in 2014, there is a $5 million milestone payment related to receiving CE Mark for AngioSculptX that the company expects to pay in the third quarter.